Evidence map›Paper›PMID 39495282›Full record

ReviewAnnals of hematology2025

A rare case of splenic marginal zone lymphoma with MYD88 mutation transformed into diffuse large B-cell lymphoma: case report and literature review.

Yuzhan Chen, Ting Chen, Shufang Fan, Qitian Mu, Guifang Ouyang

Abstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuzhan ChenDepartment of Hematology, The First Affiliated Hospital of Ningbo University, No. 59 Liuting Street, Ningbo, 315000, P. R. China.
Ting ChenDepartment of Hematology, The First Affiliated Hospital of Ningbo University, No. 59 Liuting Street, Ningbo, 315000, P. R. China.
Shufang FanDepartment of Hematology, The First Affiliated Hospital of Ningbo University, No. 59 Liuting Street, Ningbo, 315000, P. R. China.
Qitian MuLaboratory of Stem Cell Transplantation, The First Affiliated Hospital of Ningbo University, Ningbo, 315000, China.
Guifang OuyangDepartment of Hematology, The First Affiliated Hospital of Ningbo University, No. 59 Liuting Street, Ningbo, 315000, P. R. China. fyyouyangguifang@nbu.edu.cn.

Funding

Medical Science and Technology Project of Zhejiang Province 2021KY273Science and Technology Plan Project of Ningbo 2022S032
6 · The paper itself

Abstract

In indolent lymphomas, histological transformation (HT) often results in a poor prognosis and presents a significant challenge in the management of these lymphomas. Previous studies have indicated that MYD88 mutations are associated with transformation in certain haematologic malignancies. We report a rare case of splenic marginal zone lymphoma (SMZL) harbouring an MYD88 mutation, which was transformed into diffuse large B-cell lymphoma (DLBCL) and accompanied by newly emerging genetic abnormalities. The role of the MYD88 gene in SMZL is currently unclear. Through this case, we reviewed relevant studies, which indicated that MYD88 mutations, along with other genetic anomalies, may play a significant role in this process. In the future, it is essential to collect more of these rare cases for further research.

Indexed as

Cell Transformation, NeoplasticLymphoma, B-Cell, Marginal ZoneLymphoma, Large B-Cell, DiffuseMutationMyeloid Differentiation Factor 88Splenic NeoplasmsAgedHumansMaleMYD88 protein, humanMyeloid Differentiation Factor 88Diffuse large B-cell lymphomaHistological transformationMYD88 mutationSplenic marginal zone lymphoma

Identifiers

PMID39495282
PMCPMC11971140

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.